FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310112292> ?p ?o ?g. }

• W4310112292 endingPage "3650" @default.
• W4310112292 startingPage "3648" @default.
• W4310112292 abstract "The two first/last authors contributed equally Background The phase 3 SHINE trial (NCT01776840 ) showed that I+BR significantly prolonged progression free survival (PFS) versus BR with R maintenance (BR) in older patients with previously untreated mantle cell lymphoma (1L MCL) (Wang ML et al. NEJM 2022). Other commonly used 1L MCL regimens in older patients in Europe also include rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone (R-CHOP) or a modified version of this regimen where bortezomib is substituted for vincristine (VR-CAP). In the phase 3 LYM-3002 trial (NCT00722137), VR-CAP showed improved PFS, and overall survival (OS) compared to R-CHOP (Robak T et al. Lancet 2018). In the absence of a randomized comparison of I+BR versus these treatments, we performed an adjusted comparative analysis of PFS and OS with the I+BR arm from the SHINE study and the R-CHOP and VR-CAP arms from the LYM-3002 trial. Methods In SHINE trial, patients were treated with ibrutinib once daily until disease progression or unacceptable toxicity, plus 6 cycles of BR, and patients with a partial or complete response received rituximab maintenance every 8 weeks for up to 12 additional doses. In LYM-3002 trial, patients were treated with 6-8 cycles of R-CHOP or VR-CAP and did not receive maintenance therapy. PFS was the primary endpoint for both trials. To address potential confounding bias due to lack of randomization, individual patient level data of the 2 trials were used to estimate propensity scores and apply inverse probability weighting where the R-CHOP and VR-CAP arms are reweighted to match the I+BR arm to estimate the average treatment effect of the treated (ATT) (Phillippo D et al. NICE 2019, Schneeweiss S et al. Clin Pharmacol Ther 2007). Standardized mean differences (SMD) for each baseline characteristic were calculated and considered balanced between treatment cohorts if SMD ≤ 0.25 (Li F et al. JASA 2019). Relative treatment effects are presented as hazard ratios (HR) and 95% confidence intervals (CI). Results Overall, 261 patients treated with I+BR, 134 patients with R-CHOP and 130 patients with VR-CAP were included in the analyses. Baseline characteristics (Age, Morphology, Eastern Cooperative Oncology Group (ECOG), Bone Marrow, Stage, Sex, Mantle Cell Lymphoma International Prognostic Index (MIPI)) for ATT-weighted R-CHOP and VR-CAP cohorts were well balanced versus the I+BR patient cohort. When compared to R-CHOP, the ATT adjusted PFS and OS were both statistically significantly improved with I+BR. Median PFS with I+BR vs R-CHOP is 80.8 [62.0, Not reached (NR)] vs 18.4 [13.9, 20.1] months, respectively; the PFS HR is 0.24 [0.16-0.36], p<0.001. Median OS with I+BR vs R-CHOP is NR [81.2, NR] vs 64.6 [44.6, 79.0] months, respectively; the OS HR is 0.62 [0.43-0.90], p=0.012. (Figure 1) When compared to VR-CAP, the ATT adjusted PFS was statistically significantly improved with I+BR. Median PFS with I+BR vs VR-CAP is 80.8 [62.0, NR] vs 30.7 [19.6, NR] months, respectively; the PFS HR is 0.50 [0.33-0.76], p=0.001. OS was numerically improved with I+BR. Median OS with I+BR vs VR-CAP is NR [81.2, NR] vs 64.4 [51.5, NR] months, respectively; the OS HR is 0.73 [0.51-1.05], p=0.093 (Figure 1) With one additional year of follow-up of SHINE results (median follow-up of 94.5 months), there were 110 deaths in the I+BR group and 119 deaths in the BR group, and the OS HR between I+BR vs. BR is 1.00 [95% CI 0.77-1.30]. We plan to present updated adjusted indirect comparison of OS versus VR-CAP and R-CHOP at the meeting. Conclusion In this adjusted cross-trial comparative analysis, I+BR with R maintenance demonstrated improved PFS versus two commonly used 1L MCL regimens in Europe (R-CHOP and VR-CAP). This finding is consistent with the phase 3 SHINE results where the upfront ibrutinib combination is a highly effective treatment option compared to standard chemo immunotherapies for older patients with previously untreated MCL. In addition, it also potentially supports that R maintenance should be considered routinely in patients with MCL. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310112292 created "2022-11-30" @default.
• W4310112292 creator A5014103994 @default.
• W4310112292 creator A5015471289 @default.
• W4310112292 creator A5016122215 @default.
• W4310112292 creator A5028743667 @default.
• W4310112292 creator A5029354925 @default.
• W4310112292 creator A5037229747 @default.
• W4310112292 creator A5041612097 @default.
• W4310112292 creator A5050368415 @default.
• W4310112292 creator A5070371644 @default.
• W4310112292 creator A5079490154 @default.
• W4310112292 creator A5091882595 @default.
• W4310112292 date "2022-11-15" @default.
• W4310112292 modified "2023-09-30" @default.
• W4310112292 title "Ibrutinib Plus Bendamustine Plus Rituximab and Rituximab Maintenance (I+BR) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Regimen (R-CHOP) and Rituximab, Cyclophosphamide, Doxorubicin, Bortezomib, Prednisone Regimen (VR-CAP) in First-Line Mantle Cell Lymphoma Patients: An Adjusted Treatment Comparison Using Inverse Probability Weighting" @default.
• W4310112292 doi "https://doi.org/10.1182/blood-2022-158259" @default.
• W4310112292 hasPublicationYear "2022" @default.
• W4310112292 type Work @default.
• W4310112292 citedByCount "0" @default.
• W4310112292 crossrefType "journal-article" @default.
• W4310112292 hasAuthorship W4310112292A5014103994 @default.
• W4310112292 hasAuthorship W4310112292A5015471289 @default.
• W4310112292 hasAuthorship W4310112292A5016122215 @default.
• W4310112292 hasAuthorship W4310112292A5028743667 @default.
• W4310112292 hasAuthorship W4310112292A5029354925 @default.
• W4310112292 hasAuthorship W4310112292A5037229747 @default.
• W4310112292 hasAuthorship W4310112292A5041612097 @default.
• W4310112292 hasAuthorship W4310112292A5050368415 @default.
• W4310112292 hasAuthorship W4310112292A5070371644 @default.
• W4310112292 hasAuthorship W4310112292A5079490154 @default.
• W4310112292 hasAuthorship W4310112292A5091882595 @default.
• W4310112292 hasBestOaLocation W43101122921 @default.
• W4310112292 hasConcept C126322002 @default.
• W4310112292 hasConcept C143998085 @default.
• W4310112292 hasConcept C2776364478 @default.
• W4310112292 hasConcept C2776694085 @default.
• W4310112292 hasConcept C2776755627 @default.
• W4310112292 hasConcept C2777478702 @default.
• W4310112292 hasConcept C2777525834 @default.
• W4310112292 hasConcept C2777938653 @default.
• W4310112292 hasConcept C2778461978 @default.
• W4310112292 hasConcept C2778720950 @default.
• W4310112292 hasConcept C2779338263 @default.
• W4310112292 hasConcept C2779429289 @default.
• W4310112292 hasConcept C2779878957 @default.
• W4310112292 hasConcept C2780653079 @default.
• W4310112292 hasConcept C2781303535 @default.
• W4310112292 hasConcept C2781413609 @default.
• W4310112292 hasConcept C2781442060 @default.
• W4310112292 hasConcept C71924100 @default.
• W4310112292 hasConceptScore W4310112292C126322002 @default.
• W4310112292 hasConceptScore W4310112292C143998085 @default.
• W4310112292 hasConceptScore W4310112292C2776364478 @default.
• W4310112292 hasConceptScore W4310112292C2776694085 @default.
• W4310112292 hasConceptScore W4310112292C2776755627 @default.
• W4310112292 hasConceptScore W4310112292C2777478702 @default.
• W4310112292 hasConceptScore W4310112292C2777525834 @default.
• W4310112292 hasConceptScore W4310112292C2777938653 @default.
• W4310112292 hasConceptScore W4310112292C2778461978 @default.
• W4310112292 hasConceptScore W4310112292C2778720950 @default.
• W4310112292 hasConceptScore W4310112292C2779338263 @default.
• W4310112292 hasConceptScore W4310112292C2779429289 @default.
• W4310112292 hasConceptScore W4310112292C2779878957 @default.
• W4310112292 hasConceptScore W4310112292C2780653079 @default.
• W4310112292 hasConceptScore W4310112292C2781303535 @default.
• W4310112292 hasConceptScore W4310112292C2781413609 @default.
• W4310112292 hasConceptScore W4310112292C2781442060 @default.
• W4310112292 hasConceptScore W4310112292C71924100 @default.
• W4310112292 hasIssue "Supplement 1" @default.
• W4310112292 hasLocation W43101122921 @default.
• W4310112292 hasOpenAccess W4310112292 @default.
• W4310112292 hasPrimaryLocation W43101122921 @default.
• W4310112292 hasRelatedWork W2027653372 @default.
• W4310112292 hasRelatedWork W2526961449 @default.
• W4310112292 hasRelatedWork W2622060906 @default.
• W4310112292 hasRelatedWork W2889080550 @default.
• W4310112292 hasRelatedWork W2954035736 @default.
• W4310112292 hasRelatedWork W2989344576 @default.
• W4310112292 hasRelatedWork W319232779 @default.
• W4310112292 hasRelatedWork W4250202452 @default.
• W4310112292 hasRelatedWork W4281687647 @default.
• W4310112292 hasRelatedWork W4296969016 @default.
• W4310112292 hasVolume "140" @default.
• W4310112292 isParatext "false" @default.
• W4310112292 isRetracted "false" @default.
• W4310112292 workType "article" @default.